|
|
Effect of Loratadine combined with Methylprednisolone in the treatment of children with henoch chonlein purpura |
ZHU Cheng LUO Xin-fu |
Department of Pediatrics,General Hospital of Pingxiang Mining Group Co.,Ltd.,Jiangxi Province,Pingxiang 337000,China |
|
|
Abstract ]Objective To investigate the effect of Loratadine combined with Methylprednisolone in the treatment of children with henoch schonlein purpura.Methods A total of 50 children with henoch schonlein purpura treated in General Hospital of Pingxiang Mining Group Co.,Ltd.,Jiangxi Province from March 2018 to February 2020 were selected and divided into control group (25 cases) and observation group (25 cases) according to random number table method.The control group was treated with Loratadine,and the observation group was treated with Methylprednisolone.The efficacy,serum levels of inflammatory factors,improvement time of clinical symptoms and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant (P<0.05).C-reactive protein and IgA in observation group were lower than those before intervention and those in control group,the differences were statistically significant (P<0.05).The levels of complement C3 and C4 in the observation group were lower than those before intervention and in the control group,the differences were statistically significant (P<0.05).The improvement time of clinical symptoms in the observation group was shorter than that in the control group,the differences were statistically significant (P<0.05).No obvious adverse reactions occurred in both groups.Conclusion For children with henoch schonlein purpura,Loratadine combined with Methylprednisolone pulse therapy can improve the clinical efficacy of children,shorten the improvement time of clinical symptoms,improve the level of serum inflammatory factors,and does not increase adverse reactions,which has high application value.
|
|
|
|
|
[1] |
符改梅,张丽华,张小亚.氯雷他定联合甲基强的松冲击治疗小儿过敏性紫癜的临床疗效[J].贵州医药,2020,44(2):256-258.
|
[2] |
杨阳.孟鲁司特钠联合氯雷他定治疗小儿过敏性紫癜的疗效观察[J].临床研究,2019,27(11):105-106.
|
[3] |
朱伟.地氯雷他定联合甲基强的松龙冲击治疗小儿过敏性紫癜疗效观察[J].皮肤病与性病,2019,41(4):566-568.
|
[4] |
陈赛琴.评估孟鲁司特钠联合地氯雷他定治疗小儿过敏性紫癜的疗效与安全性[J].现代诊断与治疗,2019,30(11):1822-1823.
|
[5] |
于宗丽.孟鲁司特钠联合氯雷他定治疗小儿过敏性紫癜的疗效探究[J].中国处方药,2019,17(4):80-81.[6]辛颖军,李毅.甲基强的松龙治疗小儿过敏性紫癜的效果及对血清炎性因子、免疫功能及凝血功能的影响[J].临床医学研究与实践,2018,3(35):101-103.
|
[7] |
戴小萍.氯雷他定联合甲基强的松冲击疗法治疗小儿过敏性紫癜的疗效评价[J].临床医药文献电子杂志,2017,4(70):13 813.
|
[8] |
吕云.甲基强的松龙冲击治疗小儿重症过敏性紫癜的临床价值及护理分析[J].临床医学研究与实践,2017,2(24):110-111.
|
[9] |
江雄,杨军,罗耿辉,等.甲基强的松冲击治疗小儿过敏性紫癜的效果及其对患儿血清免疫学指标的影响[J].中国现代药物应用,2017,11(7):140-141.
|
[10] |
郭晓燕.氯雷他定联合甲基强的松龙冲击疗法对过敏性紫癜患儿血清免疫学指标的影响[J].北方药学,2017,14(2):143-144.
|
[11] |
严巨明,黄世华,石希均,等.氯雷他定联合甲基强的松冲击治疗小儿过敏性紫癜的临床疗效[J].现代生物医学进展,2016,16(17):3345-3347.
|
[12] |
张悦.甲基强的松龙冲击治疗小儿过敏性紫癜的临床观察[J].中国现代药物应用,2014,8(18):168-169.
|
[13] |
杨晓菲,邢伟伟,杨欢.孟鲁司特钠联合氯雷他定治疗小儿过敏性紫癜28例临床观察[J].中国皮肤性病学杂志,2015,29(11):1210-1212.
|
[14] |
王丹.甲基强的松龙冲击治疗小儿过敏性紫癜的临床疗效观察[J].中国民康医学,2015,27(17):33-34.
|
[15] |
艾力库·艾克拜.氯雷他定联合甲基强的松冲击治疗小儿过敏性紫癜的临床疗效分析[J].中西医结合心血管病电子杂志,2020,8(16):26,28.
|
|
|
|